Listen

Press releases

Receive e-mail alerts

Internal link ProQR Announces Year End 2024 Operating and Financial Results
March 13, 2025 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results
November 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
September 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
September 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results
August 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
August 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
July 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results
May 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
May 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May
April 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
March 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences
March 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
December 11, 2019 at 12:00 PM UTC
Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
November 21, 2019 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific Conferences
November 18, 2019 at 12:23 PM UTC
Internal link ProQR to Present at Upcoming Investor Conferences
November 13, 2019 at 12:00 PM UTC
Internal link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
November 06, 2019 at 12:00 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 18, 2019 at 12:20 PM UTC
Internal link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
October 16, 2019 at 03:17 AM UTC

Press releases

Internal link ProQR Announces Year End 2024 Operating and Financial Results

Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results

Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets

Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results

Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

Internal link ProQR Announces First Quarter 2023 Operating and Financial Results

Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Internal link ProQR Announces Upcoming Investor Conferences in April and May

Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Internal link ProQR to Present at Upcoming Scientific and Industry Conferences

Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Internal link ProQR to Present at Upcoming Scientific Conferences

Internal link ProQR to Present at Upcoming Investor Conferences

Internal link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Internal link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares